Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets


ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug

Author(s): Sujeeth R. Punnam, Sandeep K. Goyal, Veera Pavan K. Kotaru, Ajay R. Pachika, George S. Abela and Ranjan K. Thakur

Volume 10 , Issue 1 , 2010

Page: [73 - 81] Pages: 9

DOI: 10.2174/187152910790780032

Price: $65


Amiodarone, an iodinated benzofuran derivative, introduced in 1960s as an anti-anginal agent, emerged as a potent anti-arrhythmic agent by 1970s and is currently one of the most commonly prescribed drugs in US for ventricular and atrial arrhythmias. Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent. Because of its minimal negative inotropic activity and very low rate of pro-arrhythmia, it is considered safe in treating arrhythmias in patients with Coronary Artery Disease and Left ventricular systolic dysfunction. Despite these advantages, long-term oral therapy with amiodarone is limited by side effect profile involving various organs like thyroid, lung, heart, liver, skin etc. Though the side effects can be decreased significantly, by keeping the maintenance dose at 200 to 300 mg/day, patients on amiodarone should be followed closely. Amiodarone interacts with medications such as Warfarin, Digoxin, Macrolides, Floroquinolones etc., which share Cytochrome P450 metabolic pathway. Hence reducing their doses prior to starting amiodarone is recommended. Amiodarone, a category D drug, is contraindicated in pregnant and breast feeding women. This review discusses the pharmacokinetics of amiodarone, its evolving clinical indications, management of toxicity and drug interactions.

Keywords: Amiodarone, Atrial Fibrillation, Arrhythmias, Drug Toxicity, Ventricular Arrhythmias

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy